Patent Application
20060057229
The present invention relates to drugs for external application to the skin for inhibiting sebum secretion. More specifically, the present invention relates to drugs for inhibiting sebum secretion comprising, as an active ingredient having an excellent antagonistic effect against matrix metalloproteinase activity.
One of the pharmaceutical properties required, for a long time, for the prevention and/or improvement of acne and oily skins etc. is the effect of inhibiting sebum secretion. As conventional drugs for inhibiting sebum, there have been reported plant extracts, vitamins, female hormones, etc. Except for female hormones and some of the vitamin derivatives, however, their effect was weak and was not satisfactory. Since sebum secretion is controlled by male hormones, there have been cases in which estrogenic hormones, specifically estradiol, estrone, etc., that have an antagonistic effect against them were blended as a drug for inhibiting sebum secretion (Shin-Keshohin Gaku (New Cosmetology), page 167, Nanzando (1993)). However, they have a risk of side effects, and therefore have major limitations on the blending, and thus they are not satisfactory when they are put into practical use.
The possible mechanism of drugs for inhibiting sebum secretion is two fold: the effect of suppressing the growth of sebaceous gland cells and the effect of inhibiting the lipid synthesis of sebaceous gland cells. Since the former includes the above female hormones having potential effects, there is a need for drugs, for inhibiting sebum secretion, that exhibit equivalent effects without being accompanied by side effects (without hormone actions). However, no such substances have been found so far.
The present inventors have performed an in-depth investigation on the mechanism responsible for the growth of sebaceous gland cells and sebum secretion, and have found that matrix metalloproteinase is enhanced in the sebaceous gland cells which have come to secrete sebum in excess and, specifically, gelatinase, belonging to the matrix metalloproteinases, is enhanced. When substances inhibiting these enzymes were externally applied, the effects of lowering enzyme activity and suppressing the growth of sebaceous gland cells, and furthermore, the desired effect of inhibiting sebum secretion were found, based on which the present invention was completed. Specific experimental data are shown in Example 1 below.
Thus, the present invention relates to drugs for external application for inhibiting sebum secretion comprising a matrix metalloproteinase inhibitor as an active ingredient.
The present invention also relates to a method of inhibiting sebum secretion wherein a matrix metalloproteinase inhibitor is applied to the skin.
In
B shows the result of observation, with in situ zymography, of gelatinase in the sebaceous gland area of a human scalp. In the figure, a broken line represents the contour of the sebaceous gland area, and the white area indicated by the arrow indicates gelatin degradation activity.
In
B shows a hematoxylin-eosin stain of the skin of a mouse that was repeatedly irradiated with UVB for 10 weeks.
In
B shows the result of observation, with in situ zymography, of gelatinase behavior in the sebaceous gland area of the skin irradiated with UVB for 10 weeks. The arrow indicates the sebaceous gland area.
C shows the result of observation, with in situ zymography, of gelatinase behavior in the sebaceous gland area of the skin treated with a 10 week irradiation of UVB+EDTA (100 mM). The arrow indicates the sebaceous gland area.
In
B shows the result of in situ zymography of the skin to which a solvent was only applied, and a broken line indicates the result of the epidermal area and the sebaceous gland organ area.
In accordance with the present invention, an active ingredient of the drug for inhibiting sebum secretion may be any substance that inhibits matrix metalloproteinase, and there can be mentioned for example N-hydroxy-2(R)-[[4-methoxyphenyl)sulfonyl](3-picolyl)amino]-3-methylbutanamide (termed as active ingredient A) belonging to the hydroxamic acid derivatives, or a salt thereof, for example a hydrochloride. The structure of the hydrochloride of active ingredient A is represented by the following formula:
Furthermore, as substances that inhibit matrix metalloproteinase, there can be mentioned doxycycline having a tetracycline backbone, and curcumine, as a natural compound, for which an excellent gelatinase inhibiting effect was found, and plant extracts (turmeric extract) containing it, and the following plant extracts for which the MMPs inhibiting effect has been confirmed:
Thymus serpyllum L., Valeriana fauriei Briquet or its related plants (Valerianaceae), Diospyros kaki Thunberg (Ebenaceae), Astragalus sinicus Linne (Leguminosae), Crataegus cuneata Siebold et Zuccarini (Rosaceae), Paeonia suffruticosa Andrews (Poeonia montan Sims) (Paeoniaceae), Theasinensis Linne var. assamica Pierre (Theaceae), Eucalyptus globulus Labillardiere or its related plants (Myrtaceae), Potentilla tormentilla, Schrk (Rosaceae), Tilia cordata Mill., Tillia platyphyllus Scop., Tilia europaea Linne (Tiliaceae), Betulaalba Linne (Betulaceae), Origanum majorana L., Uncaria gambir Roxburgh (Rubiaceae), Juglans regia Linne var. sinensis De Candolle or its related plants (Juglandaceae), Sophora flavescens Aiton (Leguminosae), Sanguisorba officinalis Linne (Rosaceae), Hypericum perforatum Linne or Hypericum erectum Thunberg (Guttiferae), Thea sinensis Linne (Theaceae), Symplocos racemosa, Cyperus rotundus, Cyperus scariosus, Gaultheria fragrantissima, Acacia fornensia, Terminalia chebula, Ficus bengalensis, Cassiafistula Linn, Lyonia ovalifolia, Calophyllum inophyllum, Ficus religiosa, Persea americana Mill, Garcinia mangostan, Cocos nucifera L, Blumea balsamifera (L) DC., Woodfordia floribunda Salisb., and Cinnamomum cassin.
The constitution of the present invention will be explained below.
The present inventors have found, for the first time, that drugs for external application to the skin containing a matrix metalloproteinase antagonist for use in the present invention exhibit the effect of inhibiting the sebum secretion of the skin.
In accordance with the present invention, matrix metalloproteinases include, for example, gelatinase etc. Thus, the metalloproteinase inhibitor of the present invention is a substance that inhibits the above-mentioned matrix metalloproteinases.
Preferably, the drugs for external application containing a matrix metalloproteinase antagonist for use in the present invention are used as cosmetics for inhibiting sebum secretion, and the amount blended of the matrix metalloproteinase antagonist is 0.0001-20% by weight in tems of dry weight, preferably 0.0001-10.0% by weight relative to the total amount of the drug. When the amount is less than 0.0001% by weight, the effect mentioned in the present invention cannot be fully exhibited, and when it exceeds 20.0% by weight, it is difficult to formulate into drugs and thus is undesirable. Furthermore, the blending of the amount over 10.0% by weight does not result in significant increasess in efficacy.
In addition to the above-mentioned essential ingredients, the matrix metalloproteinase antagonist-blended drugs for external application of the present invention may be blended, as appropriate, with ingredients used for drugs for external application such, as common cosmetics and pharmaceutical drugs, including for example whitening agents, moisturizers, antioxidants, oily components, UV absorbers, surfactants, thickening agent, alcohols, powder components, coloring agents, aqueous components, water, various skin nutrients, and the like as needed.
In addition, there may be blended, as appropriate, sequestering agents such as edetate disodium, edetate trisodium, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid, caffeine, tannin, verapamil, tranexamic acid and derivatives thereof, licorice extracts, glabridin, hot water extracts of padauk fruit, various crude drugs, tocopherol acetate, drugs such as glycyrrhetic acid and derivatives thereof or salts thereof, vitamin C, ascorbic acid magnesium phosphate, ascorbic acid glucoside, arbutin, other whitening agents such as kojic acid, sugars such as glucose, fructose, mannose, sucrose and trehalose, vitamin A such as retinoic acid, retinol, retinol acetate, and retinol palmitate, and the like.
Drugs for external application to the skin containing the matrix metalloproteinase antagonist of the present invention may be any substances that are conventionally used in drugs for external application to the skin such as ointments, creams, emulsions, lotions, packs, and baths, and the dosage forms are not specifically limited.
The present invention will now be explained in more details with examples. It should be noted that the present invention is not limited by these examples. The amount blended is expressed in % by weight.
Formulation examples of active ingredient A in various dosage forms by the present invention are explained as Examples.
(Method of Preparation)
To ion exchanged water, propylene glycol, active ingredient A and caustic potash are added and dissolved, and then heated and maintained at 70° C. (aqueous phase). The other ingredients are mixed, melted under heating and maintained at 70° C. (oily phase). The oily phase is gradually added to the aqueous phase, and after the total amount has been added, the temperature is maintained for some time in order to allow a reaction to occur. It is then homogeneously emulsified by a homomixer, and cooled to 30° C. under sufficient stirring.
(Method of Preparation)
To ion exchanged water, propylene glycol is added, and heated and maintained at 70° C. (aqueous phase). The other ingredients are mixed, melted under heating and maintained at 70° C. (oily phase). The oily phase is added to the aqueous phase to pre-emulsify, and after homogeneously emulsified by a homomixer, it is cooled to 30° C. under sufficient stirring.
(Method of Preparation)
To ion exchanged water, soap powder and borax are added, dissolved under heating, and maintained at 70° C. (aqueous phase). The other ingredients are mixed, melted under heating, and maintained at 70° C. (oily phase). The oily phase is gradually added to the aqueous phase to allow a reaction to occur. After the reaction is complete, it is homogeneously emulsified by a homomixer, and after emulsification it is cooled to 30° C. under sufficient stirring.
(Method of Preparation)
To a small amount of ion exchanged water, carboxyvinyl polymer is dissolved (phase A). To the rest of the ion exchanged water, polyethylene glycol 1500 and triethanolamine are added, dissolved under heating, and maintained at 70° C. (aqueous phase). The other ingredients are mixed, melted under heating, and maintained at 70° C. (oily phase). The oily phase is added to the aqueous phase to pre-emulsify, to which phase A is added and homogeneously emulsified by a homomixer. After emulsification, it is cooled to 30° C. under sufficient stirring.
(Method of Preparation)
To ion exchanged water, propylene glycol is added, and heated and maintained at 70° C. (aqueous phase). The other ingredients are mixed, melted under heating, and maintained at 70° C. (oily phase). While the oily phase is stirred, the aqueous phase is gradually added thereto, and homogeneously emulsified by a homomixer. After emulsification, it is cooled to 30° C. under sufficient stirring.
(Method of Preparation)
To ion exchanged water, Carbopol 940 is homogeneously dissolved, while the hydrochloride of active ingredient A and polyoxyethylene (50 mole) oleylalcohol ether are dissolved and added to the aqueous phase. Then, the other ingredients are added, and caustic soda and L-arginine are added to neutralize it and to increase viscosity.
(Method of Preparation)
Phase A and phase B are separately dissolved, and phase A is added to phase C. Then phase B is added thereto and filling is performed.
(Method of Preparation)
Phase A, phase B and phase C are separately, homogeneously dissolved, and phase A is added to phase B to solubilize. Then this is added to phase C and filling is performed.
(Method of Preparation)
Powder components of talc and black iron oxide are mixed well in the blender, and then oily components of squalane to isocetyl octaoate, the hydrochloride of active ingredient A, a preservative and a flavor are added thereto, and after blending well, it is filled into a container and molded.
Tormentilla extract (dry weight)
(Method of Preparation)
After the aqueous phase is stirred under heating, a fully mixed and ground powder portion is added thereto and treated by a homomixer. After the heated and mixed oily phase is further added and treated by a homomixer, a flavor is added under stirring, and then cooled to room temperature.
Experiment 1. Detection of Gelatinase Activity in the Sebaceous Gland
(1) The Detection of Gelatinase Activity in the Human Sebaceous Gland Area
By the in situ zymography method using the FIZ-GN film by Fuji Photo Film, gelatin degradation activity at the sebaceous gland area was degraded (S. Inomata et al., J. Invest. Dermatol., 114(4):822 (2000); H. Nakamura et al., Cancer Res., Vol. 59, 467 (1999)). By staining gelatin with the Ponceau solution, the gelatin digested area (the area in which the gelatinase activity is present) was rendered white for detection.
(2) The Development of the in vivo Skin Sebaceous Gland Area and the Behavior of Gelatinase Activity
It is known that when UVB (50 mJ/cm2-200 mJ/cm2; 50 mJ/cm2 at the start of irradiation, the amount of irradiation is increased stepwise depending on the number of irradiations) below the erythema formation level is repeatedly irradiated to hairless mice, the sebaceous gland becomes developed and the amount of sebum increases (R. H. Lesnik et al., Arch Dermatol., Vol. 284, 106 (1992)).
(3) Effect of the Transdermal Application of an MMPs Inhibitor on the Sebaceous Gland
The effect of the transdermal application of an MMPs inhibitor on the sebaceous gland development and the gelatinase activity present in the sebaceous gland is shown for active substance A as an example (
Experiment 2. Experiment on the Inhibitory Effect of Various MMPs Inhibitors on Sebum Secretion
(1) Experimental Condition
UV is generally known to activate the sebaceous gland cells on the skin and thereby to enhance the amount of sebum secretion, which has been reported on a model using hairless mice (R. H. Lesnik et al., Arch Dermatol., Vol. 284, 106 (1992)). In an experiment, Bissett et al. (Phytochem. Phytobiol, Vol. 46, 3, 367 (1987)) applied the method of preparing a light-aged skin, and induced the activation of sebaceous gland cells and enhancement in the amount of sebum by irradiating the dorsal area of the hirless mice repeatedly three times per week for 5-8 weeks by controlling the amount of UVB irradiation to under the erhythema formation level.
In the course of the UV irradiation, 100 μl of 1% of the test substance was applied three times per week immediately after each UV irradiation. As the control, a group in which the solvent for the test substance was applied in a similar protocol was set up, and the effect of inhibiting sebum was evaluated by comparing the amount of sebum between the two. The measurement of sebum amount was performed using a sebumeter (COURAGE KHAZAKA company). From the measured values, the ratio (%) of sebum inhibition was calculated based on the following criteria:
As can be seen from Table 1, an excellent effect of inhibiting sebum secretion was observed for matrix metalloproteinase inhibitors, which indicates that it is a very favorable formulation method to blend a matrix metalloproteinase inhibitor as an active ingredient of the drug for inhibiting sebum secretion.
From the foregoing, the matrix metalloproteinase inhibitor-blended drugs for external application to the skin of the present invention exhibit the effect of inhibiting sebum secretion, and act favorably in preventing and/or improving acne, oily skins, keratotic plug inhibition, pore reduction, and the like.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2000-197309 | May 2000 | JP | national |
| 2001-151391 | May 2001 | JP | national |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 10277000 | Nov 2002 | US |
| Child | 11270438 | Nov 2005 | US |
